July 2019
Volume 60, Issue 9
Open Access
ARVO Annual Meeting Abstract  |   July 2019
Discriminant Proteomic Analysis of Dry Eye Syndrome and Glaucoma: Deciphering the Protein Code Underlying the Double Trouble
Author Affiliations & Notes
  • Natarajan Perumal
    Department of Ophthalmology, University Medical Centre Mainz, Mainz, Germany
  • Caroline Manicam
    Department of Ophthalmology, University Medical Centre Mainz, Mainz, Germany
  • Alexandra Tschäbunin
    Department of Ophthalmology, University Medical Centre Mainz, Mainz, Germany
  • Maya Scieranski
    Department of Ophthalmology, University Medical Centre Mainz, Mainz, Germany
  • Aline Ratcliffe
    Department of Ophthalmology, University Medical Centre Mainz, Mainz, Germany
  • Laura Gronbach
    Department of Ophthalmology, University Medical Centre Mainz, Mainz, Germany
  • Norbert Pfeiffer
    Department of Ophthalmology, University Medical Centre Mainz, Mainz, Germany
  • Franz H Grus
    Department of Ophthalmology, University Medical Centre Mainz, Mainz, Germany
  • Footnotes
    Commercial Relationships   Natarajan Perumal, None; Caroline Manicam, None; Alexandra Tschäbunin, None; Maya Scieranski, None; Aline Ratcliffe, None; Laura Gronbach, None; Norbert Pfeiffer, None; Franz Grus, None
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science July 2019, Vol.60, 263. doi:https://doi.org/
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Natarajan Perumal, Caroline Manicam, Alexandra Tschäbunin, Maya Scieranski, Aline Ratcliffe, Laura Gronbach, Norbert Pfeiffer, Franz H Grus; Discriminant Proteomic Analysis of Dry Eye Syndrome and Glaucoma: Deciphering the Protein Code Underlying the Double Trouble. Invest. Ophthalmol. Vis. Sci. 2019;60(9):263. doi: https://doi.org/.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : Dry eye (DES) and glaucoma (GLM) are two most common yet debilitating ocular disorders, which also co-occur owing to the use of GLM medication. To date, the molecular mechanisms and alterations in the regulation of protein mediators in different DES subgroups are still obscure, and inter-individual variations in disease diagnosis remain elusive. Hence, this study characterized the changes in human tear proteome to distinguish different subtypes of DES and to unravel the underlying molecular processes in a personalized basis.

Methods : Tear samples were collected with Schirmer strips from 180 individuals following stringent clinical classifications and categorized as aqueous-deficient DES (DRYaq: n=30), evaporative DES (DRYlip: n=30) and a combination of DES (DRYaqlip: n=30), glaucoma (GLM; n=20), a combination of DRYaqlip and glaucoma (GLM_DRY; n=20) and healthy subjects (CTRL; n=50). Samples were analyzed individually utilizing a targeted mass spectrometry (MS)-based proteomics strategy. The acquired continuum MS spectra were analyzed by MaxQuant computational platform followed by functional annotation and pathway analyses.

Results : A total of 128 signature peptides representing key tear protein isoforms were utilized for the targeted MS analysis. Among these, 13, 32, 33, 14 and 28 proteins were significantly (p<0.05) differentially expressed in the DRYlip, DRYaq, DRYaqlip, GLCM and GLCM_DES groups compared to CTRL, respectively. Noteworthy is that several protein clusters involved in metabolic, inflammatory and immune processes were highly activated in DRYaq, and proteins involved in lipid metabolism were significantly regulated in DRYlip. Interestingly, proteins related to heightened neurological processes were specifically regulated in both GLCM and GLCM_DES. These potential markers were also highly correlated to severity of the disease, and to age and gender. Notably, there are inter-individual variations in the expressions of specific isoforms such as S100A9, ALDH3A1, PRR4 and IGHA1.

Conclusions : This is the first study demonstrating the significant discriminant proteomic analysis of DES subtypes including GLM in a personalized manner in a large cohort. Targeted proteomics strategy was instrumental to unravel novel molecular processes in different DES for development of specific diagnosis and prognosis for both pathologies.

This abstract was presented at the 2019 ARVO Annual Meeting, held in Vancouver, Canada, April 28 - May 2, 2019.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×